Clive Maund, CliveMaund.com (4/24/23) "AGN's stock is silly cheap and so a good investment."
Douglas Loe, Leede Jones Gable (1/27/23) "Updates on Alzheimer's by three biopharmas are pertinent to PMN."
Douglas Loe, Leede Jones Gable (1/13/23) "AGN plans to initiate a Phase 2b trial of ifenprodil in chronic cough."
Douglas Loe, Leede Jones Gable (1/6/23) "We expect PMN to commence formal Phase 1 testing later this year."
Clive Maund, CliveMaund.com (12/21/22) "When AGN moves, it is likely to result in big percentage gains."
Douglas Loe, Leede Jones Gable (12/1/22) "Data presented by peers at the CTAD conference are relevant to PMN."
Dr. Andre Uddin, Research Capital Corporation (11/30/22) "Positive Phase 2a data were achieved with AGN's ifenprodil."
Steve Silver, Argus Research (10/28/22) "PMN expects to file an NDA for PMN310 with the FDA by 2022E."
Clive Maund, CliveMaund.com (10/24/22) "AGN is rated a Buy again here."
Clive Maund, CliveMaund.com (10/16/22) "AGN is rated an immediate Strong Buy."
Clive Maund, CliveMaund.com (10/10/22) "This is a good time to buy PMN stock."
Douglas Loe, Leede Jones Gable (9/30/22) "PMN peer, Eisai, reported positive Phase 3 Alzheimer's disease data."
Douglas Loe, Leede Jones Gable (9/28/22) "We are positive about PMN's PMN-310 possibly mitigating AD progression."
Clive Maund, CliveMaund.com (9/27/22) "A minor relief rally in the broad market could see AGN shoot up again."
Clive Maund, CliveMaund.com (8/23/22) "The case for buying AGN here could scarcely be stronger."
Clive Maund, CliveMaund.com (8/17/22) "AGN is rated Buy again here."
Clive Maund, CliveMaund.com (8/15/22) "AGN has the capacity to make really big moves."
Douglas Loe, Leede Jones Gable (8/5/22) "Experiments showed that PMN's PMN310 has a unique binding profile."
Dr. Andre Uddin, Research Capital Corporation (7/28/22) "It would be logical for AGN to develop ifenprodil for two indications."
Clive Maund, CliveMaund.com (7/28/22) "AGN is considered to be at another good buy spot here."
Dr. Andre Uddin, Research Capital Corporation (7/18/22) "In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."
Douglas Loe, Leede Jones Gable (7/6/22) "PMN's PMN310 could benefit from favorable FDA review of lecanemab."
Steve Silver, Argus Research (7/6/22) "PMN designated PMN267 as its lead candidate for treatment of ALS."
Steve Silver, Argus Research (6/27/22) "PMN's PMN310 potentially represents a best-in-class opportunity."
Clive Maund, CliveMaund.com (6/1/22) "AGN looks like it is shaping up for a breakout into a new bull market."
Douglas Loe, Leede Jones Gable (5/11/22) "We are initiating coverage on PMN with a Speculative Buy rating."
Steve Silver, Argus Research (4/13/22) "We view PMN's path to clinical value inflection favorably."
Clive Maund, CliveMaund.com (2/2/22) "AGN has reacted back satisfactorily to another good buy spot."
Dr. Andre Uddin, Research Capital Corporation (1/28/22) "AGN's current valuation is favorable from a risk-reward standpoint."
Clive Maund, CliveMaund.com (1/19/22) "As we can see on its latest six-month chart, AGN's stock has soared."
Bob Moriarty, 321 Gold (1/18/22) "AGN has a lot of potential, and I placed my bet with shares bought."
Clive Maund, CliveMaund.com (1/12/22) "After a 1 for 100 rollback, AGN has big upside potential."
Clive Maund, CliveMaund.com (12/22/21) "AGN stock looks like it is in the process of turning up from a low."
Clive Maund, CliveMaund.com (12/12/21) "We could soon see some good gains in AGN."
Dr. Andre Uddin, Research Capital Corporation (12/6/21) "AGN's risk/reward profile is attractive."
Jason McCarthy, Maxim Group (9/1/21) "We initiate coverage on AWKNF with a Buy rating."
Dr. Andre Uddin, Research Capital Corporation (8/4/21) "AGN is switching focus to the IPF/chronic cough indication."
David Bautz, Zacks Small-Cap Research (6/14/21) "We are very encouraged how VIV continues to expand its customer base and increase the size and frequency of orders for OxC-beta Livestock."
Sam Riches, Weekend Dispensary (5/22/21) "AGN received positive FDA feedback on its planned Phase 1 trial."
Dr. Andre Uddin, Research Capital Corporation (5/10/21) "AGN requested a meeting with the FDA to discuss advancing ifenprodil."
Joseph Gomes, Noble Capital Markets (5/4/21) "We believe VIV is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition."
Dr. Andre Uddin, Research Capital Corporation (3/1/21) "Final results from AGN's Phase 2b COVID-19 trial are expected soon."
Dr. Andre Uddin, Research Capital Corporation (2/2/21) "AGN is to continue a number of preclinical studies of DMT for stroke."
Clive Maund, CliveMaund.com (2/1/21) "AGN is starting clinical research with a psychedelic drug for stroke."
Clive Maund, CliveMaund.com (12/28/20) "The least we can expect with AGN is a significant bounce from here."
Clive Maund, CliveMaund.com (12/8/20) "AGN [shares] are now in a vigorous uptrend."
All Penny Stocks (8/24/20) "We think it is time to revisit AGN's stock as the technical stars may be aligning for one more major push higher."
Dr. Andre Uddin, Research Capital Corporation (8/19/20) "We are initiating coverage of AGN with a Speculative Buy recommendation; its lead product, ifenprodil, is being repurposed for COVID-19, idiopathic pulmonary fibrosis (IPF) and chronic cough."
Baystreet (8/12/20) "The first patient was enrolled in AGN's COVID trial of Ifenprodil."
Edward Vranic, Seeking Alpha (8/5/20) "Every COVID-19 speculative trader should consider watching RVV."
SmallCapsDaily (7/23/20) "VIV is building a compelling growth story as it has gone on to receive numerous country approvals across many large livestock markets in the world."
All Penny Stocks (5/14/20) "RVV is exploring the use of Bucillamine for the potential treatment of COVID-19."
Ed Arce, H.C. Wainwright & Co. (3/4/20) "DRRX's Phase 2b DUR-928 AH trial is set to begin in mid-2020."
Eliana Merle, Cantor Fitzgerald (3/4/20) "We see about 50–100% potential upside on approval of DRRX's Posimir."
Adam Walsh, Stifel (3/4/20) "DRRX plans to initiate the Phase 2b AH trial in mid-2020."
Francois Brisebois, Craig-Hallum Capital (3/4/20) "DRRX already exceeded enrollment in its Phase 1b NASH trial."
Mayank Mamtani, B. Riley Securities (3/4/20) "DRRX's stock presents an additional attractive entry point."
Ed Arce, H.C. Wainwright & Co. (1/3/20) "From a stock perspective, 2019 was a clear breakout year for DRRX."
Ed Arce, H.C. Wainwright & Co. (11/25/19) "DRRX has a valuable greenfield opportunity here with DUR-928."
Ed Arce, H.C. Wainwright & Co. (11/20/19) "An AdCom meeting for DRRX's POSIMIR is scheduled for Jan. 16, 2020."
Ed Arce, H.C. Wainwright & Co. (11/3/19) "DRRX's psoriasis trial is on target for topline data by year-end 2019."
Ed Arce, H.C. Wainwright & Co. (9/18/19) "DRRX's DUR-928 treatment led to improved prognosis in AH patients."
Francois Brisebois, Laidlaw & Company (9/18/19) "DRRX's Phase 2a DUR-928 study in AH showed efficacy data and safety."
Ed Arce, H.C. Wainwright & Co. (9/10/19) "DRRX earned a $10M milestone payment from Gilead."
Brian Marckx, Zacks Small-Cap Research (8/19/19) "DRRX's licensing agreement with Gilead validates the SABER technology."
Cosme Ordonez, Noble Capital Markets (8/14/19) "In Q2/19, PMN identified several antibody candidates targeting tau."
Ed Arce, H.C. Wainwright & Co. (8/2/19) "We expect substantial news flow from DRRX over the next five months."
Francois Brisebois, Laidlaw & Company (8/2/19) "Recent developments at DRRX led to a substantial influx of capital."
Cosme Ordonez, Noble Capital Markets (7/23/19) "PMN's deflated share price does not reflect the potential of PMN310."
Ed Arce, H.C. Wainwright & Co. (7/22/19) "DRRX entered an agreement allowing Gilead use of its SABER technology."
Francois Brisebois, Laidlaw & Company (7/22/19) "Its partnership with Gilead could add visibility to DRRX's DUR-928."
Ed Arce, H.C. Wainwright & Co. (7/19/19) "The FDA's response to DRRX was exceedingly fast and a positive sign."
Francois Brisebois, Laidlaw & Company (6/27/19) "DRRX's capital raise takes care of financing overhang on the stock."
Brian Marckx, Zacks Small-Cap Research (6/27/19) "The market for DRRX's POSIMIR could be substantial."
Ed Arce, H.C. Wainwright & Co. (6/19/19) "DRRX can initiate the Phase 2a DUR-928 study's 150 mg dosing cohort."
Brian Marckx, Zacks Small-Cap Research (5/16/19) "Early data from DRRX's Phase 2a trial in AH are highly compelling."
Cosme Ordonez, Noble Capital Markets (5/15/19) "PMN presented progress in its Parkinson's program, at AP/PD 2019."
Francois Brisebois, Laidlaw & Company (5/13/19) "We are encouraged by DRRX's clinical timeline remaining on track."
Clive Maund, CliveMaund.com (5/12/19) "PMN's stock is now showing signs that it is ready to advance anew."
Ed Arce, H.C. Wainwright & Co. (5/9/19) "Data from DRRX's DUR-928 trial in AH showed meaningful improvements."